LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
48.88
+0.63 (1.30%)
Feb 5, 2025, 11:42 AM EST - Market open
LivaNova Revenue
LivaNova had revenue of $318.12M in the quarter ending September 30, 2024, with 11.19% growth. This brings the company's revenue in the last twelve months to $1.24B, up 11.04% year-over-year. In the year 2023, LivaNova had annual revenue of $1.15B with 12.89% growth.
Revenue (ttm)
$1.24B
Revenue Growth
+11.04%
P/S Ratio
2.11
Revenue / Employee
$428,186
Employees
2,900
Market Cap
2.65B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.15B | 131.74M | 12.89% |
Dec 31, 2022 | 1.02B | -13.56M | -1.31% |
Dec 31, 2021 | 1.04B | 101.12M | 10.82% |
Dec 31, 2020 | 934.24M | -149.93M | -13.83% |
Dec 31, 2019 | 1.08B | -22.79M | -2.06% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Apr 24, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
LIVN News
- 15 days ago - LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results - Business Wire
- 7 weeks ago - RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression - Business Wire
- 2 months ago - LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting - Business Wire
- 2 months ago - LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences - Business Wire
- 3 months ago - LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints - Business Wire
- 3 months ago - LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - LivaNova Reports Third-Quarter 2024 Results - Business Wire
- 3 months ago - LivaNova: Economics Should Start Making Sustained Improvements - Seeking Alpha